Nexagon (Gap Junction Peptide)
Overview
Nexagon is a synthetic peptide designed to transiently modulate gap junction intercellular communication by mimicking a segment of the connexin protein family. The mechanism involves temporary inhibition of connexin43-mediated channels during the early inflammatory phase of wound healing, which may reduce inflammatory cell infiltration and subsequent scar formation.
Mechanism of Action
This approach aims to shift the healing process toward regeneration rather than fibrosis.
Research Summary & Key Findings
Early clinical studies in venous leg ulcers demonstrated improved healing rates and reduced scar tissue formation. A phase II trial showed statistically significant reduction in scar size when applied topically to acute wounds, though larger confirmatory trials have not been widely published.
Clinical Status
Nexagon (Gap Junction Peptide) is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed — "Nexagon"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Nexagon"
Registered interventional and observational studies, including status and phase.
- PubChem — "Nexagon"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Recovery
BPC-157
Research PhaseA synthetic gastric pentadecapeptide derived from a protein found in human gastric juice. BPC-157 promotes angiogenesis ...
View detailsTB-500 (Thymosin Beta-4)
In Clinical TrialsThymosin Beta-4 is a 43-amino acid actin-sequestering protein involved in cell migration, differentiation, and tissue re...
View detailsGHK-Cu
Research PhaseA naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine) found in human plasma, saliva, and urine. G...
View detailsDSIP (Delta Sleep-Inducing Peptide)
Research PhaseA naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) originally isolated from cerebral venous blood o...
View detailsStart Your Consultation
Get an AI-proposed Nexagon (Gap Junction Peptide) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Nexagon (Gap Junction Peptide).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.